Table 1 Clinical characteristics of patients included in the analysis
From: Prediction of malignant esophageal fistula in esophageal cancer using a radiomics-clinical nomogram
Characteristics | Primary set | Validation set | χ2/Z | P | ||
|---|---|---|---|---|---|---|
Non-fistula | Fistula | Non-fistula | Fistula | |||
Subjects | 48 | 38 | 21 | 15 | Â | Â |
Age (mean ± SD) | 63.813 ± 10.097 | 62.026 ± 9.545 | 64.0476 ± 6.888 | 60 ± 7.339 | 0.478 | 0.633 |
Length (mean ± SD) | 6.315 ± 2.239 | 6.297 ± 2.278 | 5.924 ± 2.497 | 6.8 ± 2.908 | 0.328 | 0.743 |
Gender | ||||||
 Female | 8 (16.67%) | 3 (7.89%) | 3 (14.29%) | 2 (13.33%) |  |  |
 Male | 40 (83.33%) | 35 (92.11%) | 19 (90.48%) | 13 (86.67%) | 0.012 | 0.913 |
Stage_T | ||||||
 T2 | 1 (2.08%) | 2 (5.26%) | 2 (9.52%) | 0 (0.00%) |  |  |
 T3 | 30 (62.50%) | 16 (42.11%) | 15 (71.43%) | 7 (46.67%) |  |  |
 T4 | 17 (35.42%) | 20 (52.63%) | 4 (19.05%) | 8 (53.33%) | 1.122 | 0.571 |
Stage_N | ||||||
 N0 | 6 (12.50%) | 3 (7.89%) | 2 (9.52%) | 3 (20.00%) |  |  |
 N1 | 19 (39.58%) | 16 (42.11%) | 9 (42.86%) | 6 (40.00%) |  |  |
 N2 | 16 (33.33%) | 15 (39.47%) | 7 (33.33%) | 4 (26.67%) |  |  |
 N3 | 7 (14.58%) | 4 (10.53%) | 3 (14.29%) | 2 (13.33%) | 0.511 | 0.917 |
Stage_M | ||||||
 M1 | 15 (31.25%) | 12 (31.58%) | 10 (47.62%) | 8 (53.33%) |  |  |
 M0 | 33 (68.75%) | 26 (68.42%) | 11 (52.38%) | 7 (46.67%) | 3.773 | 0.052 |
Location | ||||||
 Upper | 10 (20.83%) | 10 (26.32%) | 6 (28.57%) | 4 (26.67%) |  |  |
 Middle | 17 (35.42%) | 15 (39.47%) | 10 (47.62%) | 6 (40.00%) |  |  |
 Lower | 21 (43.75%) | 13 (34.21%) | 5 (23.81%) | 5 (33.33%) | 1.521 | 0.467 |
Radiation | ||||||
 Y | 34 (70.83%) | 26 (68.42%) | 11 (52.38%) | 9 (60.00%) |  |  |
 N | 14 (29.17%) | 12 (31.58%) | 10 (47.62%) | 6 (40.00%) | 2.271 | 0.132 |
Fraction dose | ||||||
 < 2 GY | 14 (29.17%) | 13 (34.21%) | 5 (23.81%) | 3 (20.00%) |  |  |
 ≥ 2 GY | 20 (41.67%) | 13 (34.21%) | 6 (28.57%) | 6 (40.00%) | 1.671 | 0.196 |
Total dose | ||||||
 < 60 GY | 14 (29.17%) | 20 (52.63%) | 5 (23.81%) | 5 (33.33%) |  |  |
 ≥ 60 GY | 20 (41.67%) | 6 (15.79%) | 6 (28.57%) | 4 (26.67%) | 0.269 | 0.604 |
Chemoradiotherapy | ||||||
 Y | 13 (27.08%) | 12 (31.58%) | 5 (23.81%) | 4 (26.67%) |  |  |
 N | 23 (47.92%) | 12 (31.58%) | 6 (28.57%) | 5 (33.33%) | 0.068 | 0.794 |
Stenosis | ||||||
 Y | 11 (22.92%) | 19 (50.00%) | 3 (14.29%) | 4 (26.67%) |  |  |
 N | 37 (77.08%) | 19 (50.00%) | 18 (85.71%) | 11 (73.33%) | 2.863 | 0.09 |
Chemotherapy | ||||||
 Y | 45 (93.75%) | 34 (89.47%) | 21 (100.00%) | 14 (93.33%) |  |  |
 N | 3 (6.25%) | 4 (10.53%) | 0 (0.00%) | 1 (6.67%) | 1.191 | 0.275 |
Chemotherapy regimena | ||||||
 Tb | 35 (72.92%) | 29 (76.32%) | 15 (71.43%) | 12 (80.00%) |  |  |
 Fc | 10 (20.83%) | 5 (13.16%) | 6 (28.57%) | 2 (13.33%) | 0.266 | 0.635 |